Dr. Nelson Teng, M.D., Ph.D., is a managing partner at Charter Life Sciences, an early-stage healthcare fund, and chief of gynecologic oncology at Stanford University's School of Medicine.
Nelson was a founder of several companies, including women's healthcare company Adeza Biomedical (acquired by Hologic), biotechnology company Univax Biologics (IPO on NASDAQ in 1992, then acquired by NABI), medical device company Vesta (acquired by Pfizer), and biologics company SeraCare Life Sciences (NASDAQ: SRLS). Nelson also has extensive experience in Asia and has been an advisor to Asian governments and Asia-based venture capital funds.
Nelson received a Ph.D. in biophysics from the University of California, Berkeley, a M.D. from the University of Miami and is a graduate of the postgraduate program at the Stanford University Graduate School of Business.